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Abstract
Background: In breast cancer patients, HER2 overexpression is routinely assessed by immunohistochemistry (IHC) and
equivocal cases are subject to fluorescent in situ hybridization (FISH). Our study compares HER2 scoring by histopathologists
with automated quantitation of staining, and determines the concordance of IHC scores with FISH results.
Methods: A tissue microarray was constructed from 1,212 invasive breast carcinoma cases with linked treatment and outcome
information. IHC slides were semi-quantitatively scored by two independent pathologists on a range of 0 to 3+, and also analyzed
with an Ariol automated system by two operators. 616 cases were scorable by both IHC and FISH.
Results: Using data from unequivocal positive (3+) or negative (0, 1+) results, both visual and automated scores were highly
consistent: there was excellent concordance between two pathologists (kappa = 1.000, 95% CI: 1-1), between two machines
(kappa = 1.000, 95% CI: 1-1), and between both visual and both machine scores (kappa = 0.898, 95% CI: 0.775–0.979). Two
pathologists successfully distinguished negative, positive and equivocal cases (kappa = 0.929, 95% CI: 0.909–0.946), with excellent
agreement with machine 1 scores (kappa = 0.835, 95% CI: 0.806–0.862; kappa = 0.837, 95% CI: 0.81–0.862), and good agreement
with machine 2 scores (kappa = 0.698, 95% CI: 0.6723–0.723; kappa = 0.709, 95% CI: 0.684–0.732), whereas the two machines
showed good agreement (kappa = 0.806, 95% CI: 0.785–0.826). When comparing categorized IHC scores and FISH results, the
agreement was excellent for visual 1 (kappa = 0.814, 95% CI: 0.768–0.856), good for visual 2 (kappa = 0.763, 95% CI: 0.712–
0.81) and machine 1 (kappa = 0.665, 95% CI: 0.609–0.718), and moderate for machine 2 (kappa = 0.535, 95% CI: 0.485–0.584).
Conclusion: A fully automated image analysis system run by an experienced operator can provide results consistent with visual
HER2 scoring. Further development of such systems will likely improve the accuracy of detection and categorization of
membranous staining, making this technique suitable for use in quality assurance programs and eventually in clinical practice.
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Background
HER2/neu (also known as c-erbB-2) is a member of the
ErbB protein family, more commonly known as the epi-
dermal growth factor receptor (EGFR) family. The HER2
protein is a cell membrane surface-bound receptor tyro-
sine kinase that is involved in signal transduction path-
ways leading to cell growth and differentiation [1]. HER2
is a proto-oncogene located on the long arm of human
chromosome 17 (17q11.2-q12). Overexpression of the
protein, typically caused by amplification of the HER2
gene, leads to constitutive activity of the HER2 receptor
and breast tumor development through enhanced cell
proliferation, survival, motility and adhesion [2]. HER2
gene amplification has been reported in 10–35% of inva-
sive breast carcinomas, and it is associated with an aggres-
sive disease course, increased disease recurrence, and
decreased disease-free and overall survival in lymph node-
positive patients [2-5]. In addition to its prognostic role,
HER2 has now become more important as a predictive
marker of treatment response to Trastuzumab, a human-
ized murine monoclonal antibody to the HER2 protein.
In 1998, Trastuzumab (marketed as Herceptin, Genen-
tech, San Francisco, California, USA) was approved for the
targeted therapy of HER2-overexpressing metastatic breast
cancer patients by the Food and Drug Administration
(FDA) of the USA, and it has also recently been shown to
be very effective in the adjuvant setting [2].
The effectiveness of Herceptin therapy depends on accu-
rately evaluating HER2 status, which can be done either
by immunohistochemical (IHC) assessment of HER2 pro-
tein expression or by evaluating HER2 gene amplification
using in situ hybridization (ISH), most commonly, fluo-
rescent ISH (FISH). FISH shows excellent sensitivity and
specificity in detecting the HER2 gene amplification [6].
IHC assessment of HER2 status is an inexpensive and rel-
atively standardized method that can be performed in all
pathology laboratories. Of the various HER2 antibodies
available, the FDA-approved Dako Herceptest (Dako,
Glostrup, Denmark) has been considered the most relia-
ble [7]. However, new antibodies such as Ventana PATH-
WAY anti-HER2/neu (4B5) rabbit monoclonal antibody
also provide excellent sensitivity, specificity, and inter-
laboratory reproducibility [8]. Based on the determina-
tion of staining intensity and percentage of cells with
complete membrane staining, the results are scored semi-
quantitatively on a range of 0 to 3+. According to these
four-tier criteria, 0 and 1+ scores are considered negative,
3+ score is positive, while 2+ is equivocal (weakly posi-
tive) and requires confirmation by FISH [9-11]. The
intraobserver reproducibility is generally satisfactory for
both the percentage of positive cells and membrane stain-
ing [12-15]. The inter-observer agreement is excellent for
scoring classes 0, 1+ and 3+ [11,16-19]. However, the
determination of staining intensity and percentage of cells
with complete membrane staining is subjective. This
results in high inter-observer variability in assigning a 2+
score [11,17,20,21] and in discriminating between 2+ and
3+ classes [12]. Consequently this leads to a high rate of
false-positives for intermediate IHC scores [22-24].
According to the HercepTest guidelines, cases with more
than 10% of tumor cells showing strong circumferential
membrane staining are classified as 3+. The American
Society of Clinical Oncology/College of American Pathol-
ogists (ASCO/CAP) guidelines recommend using a 30%
cut-off, in order to decrease the incidence of false positive
cases [25].
It has been suggested that the use of digital microscopy
improves the accuracy and inter-observer reproducibility
of HER2 IHC analysis. Digital measurement of staining
intensity is more accurate than assessment with a human
eye because it is not influenced by factors such as the
ambient light or pathologist fatigue [26,27]. We have
recently shown that automated quantitation of estrogen
receptor (ER) immunostaining yields results that do not
differ from human scoring against dextran-coated char-
coal biochemical assay and the most important clinico-
pathologic correlate, patient outcome [28]. Consistent,
objective and reproducible results for HER2 assessment
can be generated by a number of available automated
scoring systems such as the automated cellular imaging
system (ACIS) (ChromaVision, Inc, San Juan Capistrano,
California, USA) [29,30] optimized for use with Dako
HercepTest, Micrometastasis Detection System (MDS,
Applied Imaging, San Jose, California, USA) [31],
Extended Slide Wizard (Tripath Imaging, Inc. Burlington,
North Carolina, USA) and others [32-34].
To determine the inter-observer variability, we have com-
pared results of visual and automated scoring of HER2
immunostaining on TMAs constructed from invasive
breast carcinomas, with data from 1,413 cases used for
FISH analysis. 616 cases were scorable by both methods.
We then evaluated the concordance of IHC and FISH
results and performed Kaplan-Meier survival analysis to
determine the prognostic significance of different analyses
of HER2 status.
Methods
In this study, we used IHC data from 1,212 patients and
FISH data from 616 patients. The data were derived from
a series of 4,046 cases of invasive breast carcinoma diag-
nosed in 1986–1992, referred to the British Columbia
Cancer Agency (BCCA) for treatment, and assembled into
17 tissue microarray (TMA) blocks. Ethical approval for
the study was obtained from the Clinical Research Ethics
Board of the BCCA [28]. Previously frozen breast cancer
tissue samples were fixed in 10% neutral buffered forma-
lin, embedded in paraffin and used to construct TMAsBMC Cancer 2009, 9:165 http://www.biomedcentral.com/1471-2407/9/165
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consisting of 0.6 mm tissue cores using a manual arrayer
(Beecher Instruments, Inc., Silver Springs, Maryland,
USA) as previously described [35,36].
From each TMA block, 4 μm thick sections were cut and
immunostained on Ventana Benchmark XT staining sys-
tem (Ventana Medical Systems, Tucson, Arizona, USA).
Sections were deparaffinized in xylene, dehydrated
through three alcohol changes and transferred to Ventana
Wash solution. Endogenous peroxidase activity was
blocked in 3% hydrogen peroxide. Slides were then incu-
bated with Ventana PATHWAY anti-HER2/neu (4B5) rab-
bit monoclonal antibody at 37°C for 32 min and
developed in DAB for 10 min. Finally, sections were coun-
terstained with hematoxylin and mounted.
HER2 was scored visually by two independent patholo-
gists (BG, GT) according to the HercepTest guidelines: 0
(negative): no staining is observed, or membrane staining
is observed in <10% of the tumor cells; 1+ (negative): a
faint/barely perceptible membrane staining is detected in
>10% of tumor cells; the cells exhibit incomplete mem-
brane staining; 2+ (weakly positive, equivocal): a weak to
moderate complete membrane staining is observed in
>10% of tumor cells; and 3+ (strongly positive): a strong
complete membrane staining is observed in >10% of
tumor cells. Only six 3+ cases (0.5%) showed heterogene-
ous staining, i.e. would have been interpreted as 2+ by
ASCO/CAP guidelines. Therefore, the scoring system used
in this study would not impact the results and conclu-
sions. Scores were entered into a standardized Excel work-
sheet with a sector map matching each TMA section. Cases
were not included in the statistical analysis if there was no
tumor tissue in the cores or the cores were cut through.
Original scoring grids were converted to tables using
Deconvoluter 1.10 [37] and combined in a single text file
with TMA-Combiner 1.00 [38]. The resulting text files
were imported into SPSS 15.0 and R2.4.0 for Windows
[39].
The same slides were digitized with a commercial image
analysis system Ariol (Applied Imaging Inc., San-Jose, Cal-
ifornia, USA). For clinical lab applications, Ariol has
received FDA clearance as an aid to pathologists in the
detection, classification, and counting of cells of a partic-
ular color, intensity, size, pattern, and shape. Applied
Imaging has received additional FDA 510(k) clearances
for specific applications, including immunohistochemical
assessment of HER2 in breast cancer. The Ariol system is
based on an Olympus microscope with motorized stage
and autofocus capabilities, and equipped with a black and
white video camera. We regularly performed bright-field
calibration using the Calibration slide to ensure accurate
scanning and analysis. The system was set to Kohler illu-
mination to capture high quality images. Slides were
scanned at 20× objective magnification with three filters:
red, green and blue. Ariol software, which converts these
three-channel images into color reconstructions, was used
for image analysis. The program was trained by a pathol-
ogist (DT) using representative cores containing areas that
would be scored as 1+ and 3+ visually. Using the color
pickup tool within the Ariol image analyzer, we selected
membranes with weak positive staining and assigned "1+
intensity"; we then selected the membranes with strong
positivity and assigned "3+ intensity". Similarly, we
selected counterstained nuclei with the color pickup tool,
and adjusted the desired size, roundness and other shape
parameters under visual control. Numeric values for
colors of the positive objects, i.e. membranes, and nega-
tive objects, i.e. nuclei, were stored on the hard drive in a
color classifier file. Numeric values for the shape of the
nuclei were stored in a separate shape classifier file. The
program used these two files for segmentation of the
nuclei and the membranes in all other cores, and these
two files were sent out to be used in the machine 2. Scores
from a "0" to a "3+" were automatically generated by the
Ariol image analysis software for each core, based on the
intensity and completeness of the positively stained mem-
branes, and the percent of positive cells. The Ariol algo-
rithm applies HercepTest criteria for the score
calculations. Visual examples and a graphical explanation
are given in Figure 1. The training step increases the spe-
cificity of the analysis as it ensures that extracellular matrix
and most stromal cells are excluded from image analysis,
and it allows the program to calculate percent of positive
tumor cells more precisely. After the program training on
one of the representative TMA cores, the rest of the analy-
sis was performed without human supervision. All tissue
cores were analyzed in toto; no specific pathologist selec-
tion of tumor tissue within the cores was made following
the training step. For statistical analysis, we selected only
cores with at least 50 tumor cells detected, i.e. all cores
with less than 50 cells were considered unscorable. To get
an estimate of the demands posed on the operator of the
Ariol system, the same slides were scanned and processed
on an identical Ariol system by an operator with less than
one week experience working with this particular Ariol
script (KM). The descriptors of the color and shape of the
positive and negative tumor cells were transferred from
one system to another, therefore variations in the image
analysis results depended only on the scanner settings, i.e.
brightfield calibration, positioning and white balance, but
not on the image analysis settings.
The hematoxylin and eosin and IHC images of all cores
used in this study are publicly available at the companion
site [40]. The site was constructed using Genetic Pathol-
ogy Evaluation Centre (GPEC) database and a Java applet
provided by Bacus Laboratories, Inc. All slides were
scanned with a BLISS scanner (Bacus Laboratories, Inc.,BMC Cancer 2009, 9:165 http://www.biomedcentral.com/1471-2407/9/165
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Schematic illustration of automated HER2 scoring Figure 1
Schematic illustration of automated HER2 scoring. a) Image analysis system Ariol (Applied Imaging Inc., San-Jose, CA). 
b) Training window displaying the 3+ membrane and nuclear colors with fill mask. c) Outline of membrane as detected by the 
color classifier for the 3+ membrane color class. d) The border mask of nuclei as detected by the color classifier for the 3+ 
nuclei color class.BMC Cancer 2009, 9:165 http://www.biomedcentral.com/1471-2407/9/165
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Lombard, Illinois, USA), and posted on the site. WebSlide
Browser for Windows (Bacus Laboratories, Inc., Lombard,
Illinois, USA) can be used for viewing preview images of
the arrays and images of individual cores.
Six-micron sections of the TMA slides were hybridized
with probes to LSI HER2 and CEP17 with the PathVys-
ion™ HER2 DNA Probe Kit using a modified protocol, as
previously described [41]. Analysis of FISH signals was
performed using Metasystems™ automated image acquisi-
tion and analysis system, Metafer (Metasystems, Alt-
lussheim, Germany). This automated system scores FISH
signals by employing specific measurement algorithms to
detect and quantify clustered signals. Average copy
number for each probe was calculated and the amplifica-
tion ratio (ratio between the average copy per cell for Her2
and the average copy for centromere 17) determined
(MC). HER2 amplification was defined as a HER2/CEP17
ratio of 2.2 or more. A HER2/CEP17 ratio <1.8 was con-
sidered negative for HER2 amplification, and a ratio at or
near the cut-off (1.8–2.2) was interpreted as equivocal.
Tumors that failed to hybridize were not included in the
analysis. We only accepted scores if >40 tiles were
counted. With Metafer system, one tile is considered one
cell as the size of a tile is approximately the average size of
a nucleus. Normal cells were excluded wherever possible,
and the corresponding H&E slides were reviewed when
needed.
For statistical analysis, we used data from 1212 patients
for the IHC and 616 patients for the IHC/FISH compari-
sons. Exclusion criteria included core drop-off during
processing, insufficient or absent tumor tissue within the
cores, and artifactual distortion of the tissue making dis-
crimination of cellular structure impossible. Statistical
analysis was performed in SPSS 15.0 for Windows (SPSS
Inc., Chicago, Illinois) and R 2.4.0 [39]. All tests were two-
sided and used a 5% alpha level to determine significance.
95% bootstrapped confidence intervals were calculated
using the adjusted bootstrap percentile (bias-corrected
and accelerated) method [42]. Breast cancer specific sur-
vival was estimated using Kaplan-Meier curves and sur-
vival differences were determined by log-rank tests. We
used the open-source R 2.4.0 package to calculate differ-
ences between kappa statistics from visual to automated
scoring comparisons; a permutation test with 10,000 per-
mutations was implemented.
Results
IHC and FISH results
The number of cases scorable by all four observers (visual
or machine) on IHC slides, regardless of FISH status was
1,212 (30%). Of 4,046 cases analyzed, FISH was success-
fully performed in 1413 cases (34.9%). Of 1,413 FISH
scorable cases, HER2 was amplified (HER2/CEP17 ratio
of 2.2 or more) in 252 cases (17.8%). Borderline HER2
amplification (HER2/CEP17 ratio 1.8–2.2) was seen in 77
cases (5.4%), and 1084 cases (76.7%) were found to be
non-amplified (HER2/CEP17 ratio <1.8). The number of
cases scorable by both IHC and FISH, including FISH
equivocal cases, was 616. Table 1 shows the full break-
down of data by FISH and IHC scored by the four observ-
ers.
Analysis of HER2 IHC inter-observer variability by Kappa 
statistics
Inter-observer variability was estimated by comparing the
visual scores of two pathologists, and the automated
scores generated by two operators on two different Ariol
hardware systems. Comparison of categorized variables
({0, 1+} versus {2+} versus {3+}) from 1,212 patients
using weighted kappa statistics (R function wkappa(ψ)
Table 1: Comparison of FISH and IHC results in 616 cases
FISH-amplified (n = 185)
01 + 2 + 3 +
Visual 1 9 (4.9%) 9 (4.9%) 30 (16.2%) 137 (74.1%)
Visual 2 19 (10.3%) 12 (6.5%) 29 (15.7%) 125 (67.6%)
Machine 1* 0 (.0%) 36 (19.5%) 79 (42.7%) 70 (37.8%)
Machine 2* 0 (.0%) 41 (22.2%) 137 (74.1%) 7 (3.8%)
FISH-non-amplified (n = 394)
01 + 2 + 3 +
Visual 1 293 (74.4%) 78 (19.8%) 15 (3.8%) 8 (2.0%)
Visual 2 315 (79.9%) 59 (15.0%) 13 (3.3%) 7 (1.8%)
Machine 1* 1 (0.3%) 372 (94.4%) 17 (4.3%) 4 (1.0%)
Machine 2* 4 (1.0%) 375 (95.2%) 15 (3.8%) 0 (.0%)
FISH-equivocal (n = 37)
01 + 2 + 3 +
Visual 1 14 (37.8%) 12 (32.4%) 7 (18.9%) 4 (10.8%)
Visual 2 18 (48.6%) 8 (21.6%) 6 (16.2%) 5 (13.5%)
Machine 1* 0 (.0%) 25 (67.6%) 9 (24.3%) 3 (8.1%)
Machine 2* 2 (5.4%) 23 (62.2%) 11 (29.7%) 1 (2.7%)
*Only cores with more than 50 cells were considered scorable on the 
Ariol system.BMC Cancer 2009, 9:165 http://www.biomedcentral.com/1471-2407/9/165
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using squared weights) showed excellent inter-observer
agreement: for visual 1 versus visual 2 scores, kappa =
0.929 (95% CI: 0.909–0.946), visual 1 versus machine 1
scores, kappa = 0.835 (95% CI: 0.806–0.862), and visual
2 versus machine 1 scores, kappa = 0.837 (95% CI: 0.81–
0.862); good agreement was seen between machine 2 and
visual 1, kappa = 0.698 (95% CI: 0.672–0.723), machine
2 and visual 2, kappa = 0.709 (95% CI: 0.684–0.732), and
machine 1 and machine 2, kappa = 0.806 (95% CI:
0.785–0.826) (Table 2).
When comparing binarized IHC scores (0, 1+ {negative}
versus 3+ {positive}) in a set of 849 patients (363 cases
with 2+ scores were excluded), the kappa values were
within 'excellent' agreement range: for two visual scores,
kappa = 1.000 (95% CI: 1-1); for two machine scores,
kappa = 1.000 (95% CI: 1-1); for visual 1 versus both
machine scores, kappa = 0.898 (95% CI: 0.775–0.979);
and for visual 2 versus both machine scores, kappa =
0.898 (95% CI: 0.775–0.979), (Table 3).
We also performed Kappa permutation test to assess
whether the HER2 IHC scores differed in their ability to
match the gold standard. This test included categorized
variables (n = 352) to assess the ability of the HER2 score
to indicate negative (0, 1+) versus equivocal (2+) versus
positive (3+) cases where visual 1 IHC score is the gold
standard (Table 4). The permutation test could not be
done for binarized IHC scores because there were only
229 cases available for analysis when visual 1 IHC was
used as the gold standard, and 382 cases were available
when FISH was used as the gold standard. There were no
discrepant cases between visual 1 and visual 2, with only
one discrepant case between both visual scores and both
machines.
Concordance of IHC and FISH results by Kappa statistics
The concordance of IHC and FISH results was analyzed
using binarized and categorized variables by Kappa statis-
tics. When comparing categorized IHC scores (0, 1+ (neg-
ative) versus 2 (equivocal) versus 3+ (positive)) with FISH
results in a set of 616 patients, the agreement was excel-
lent for visual 1 (kappa = 0.814, 95% CI: 0.768–0.856),
good for visual 2 (kappa = 0.763, 95% CI: 0.712–0.81),
and machine 1 (kappa = 0.665, 95% CI: 0.609–0.718),
while machine 2 showed moderate agreement with FISH
results (kappa = 0.535, 95% CI: 0.485–0.584) (Table 5).
When comparing binarized IHC scores (0, 1+ {negative}
versus 3+ {positive}) and FISH results in a set of 382
patients (234 cases with 2+ scores were excluded), FISH
data only showed fair agreement with all four IHC scores:
visual 1 (kappa = 0.328, CI: 0.0955 – 0.537), visual 2
(kappa = 0.328, CI: 0.0914 – 0.538), machine 1 (kappa =
0.343 (0.101 – 0.558), and machine 2 (kappa = 0.343
(0.0935 – 0.555) (Table 5). This was likely caused by the
large number of 2+ scores excluded (n = 234) and low
number of 3+ scores (n = 6) available for this analysis.
Therefore, the proportion of HER2-positive and HER2-
negative cases was not fairly represented for the concord-
ance analysis of the binarized data.
The clinical consequences of using a machine for HER2
scoring are summarized in Table 6. Automated scoring on
the Ariol machine would result in more 2+ scores (2–3
times as many as visual scoring) with a consequent
increase of FISH assessments in clinical practice.
Kaplan-Meier survival analysis
For 1,212 patients whose tissue cores were scorable by all
four observers on IHC slides, median age at diagnosis was
59 years, and median follow-up time was 12.24 years.
Clinical-pathological characteristics of these patients are
summarized in Table 7.
Kaplan-Meier survival analysis of cases stratified based on
the HER2 status, as determined by visual or machine scor-
ing of the immunostained slides, is shown in Figure 2.
Results of the log-rank tests with P values in a set of 1,210
patients (outcome information was not available in 2
cases), stratified as 0 (negative), 1+ (weak), 2+ (equivocal)
and 3+ (positive) are as follows: visual scoring 1 χ2 =
60.281, P = 5.12 × 10-13; visual scoring 2 χ2 = 56.037, P =
4.13 × 10-12; machine scoring 1 χ2 = 57.453, P = 2.06 × 10-
12; machine scoring 2 χ2 = 62.232, P = 1.96 × 10-13 (Figure
2). After binarization of the scores as either HER2-positive
or HER2-negative in a set of 848 patients, the results of
log-rank test were: visual scoring 1 χ2 = 26.245, P = 3.01 ×
10-7; visual scoring 2 χ2 = 26.245, P = 3.01 × 10-7; machine
scoring 1 χ2 = 56.757, P = 4.93 × 10-14; machine scoring 2
χ2 = 56.757, P = 4.93 × 10-14 (Figure 3).
Table 2: Weighted Kappa statistics on the whole cohort for comparison of inter-observer concordance for categorized HER2 IHC 
variables (n = 1212)
V i s u a l  1V i s u a l  2M a c h i n e  1
Visual 1 ---
Visual 2 0.929 (0.909 – 0.946) - -
Machine 1 0.835 (0.806 – 0.862) 0.837 (0.810 – 0.862) -
Machine 2 0.698 (0.672 – 0.723) 0.709 (0.684 – 0.732) 0.806 (0.785 – 0.826)BMC Cancer 2009, 9:165 http://www.biomedcentral.com/1471-2407/9/165
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The permutation analysis in a set of 615 patients (out-
come information was not available for one patient)
showed that the differences in prognostic significance of
these different analyses of HER2 status are not statistically
significant, i.e. visual and machine scoring show similar
results for categorized variables (Table 8). The permuta-
tion analysis could not be performed for binarized varia-
bles because after excluding 2+ scores, only 382 cases were
available for analysis and there were no discrepant cases
between the visual scores and between the machine
scores, only 1 discrepant score between visual 1 and
machine 1, and 19 discrepent scores between visual 1 and
FISH results.
Discussion
In breast cancer patients, determination of prognosis and
treatment strategies based on HER2 status greatly depends
on the accurate evaluation of HER2 overexpression by
IHC and/or FISH. HER2 immunohistochemistry is an
inexpensive method that can be performed readily in all
pathology laboratories on either standard paraffin sec-
tions or TMA sections [43]. However, consensus regarding
the best methods, reagents, or cut-off points to determine
HER2 status is still debated [25,28,44-46]. TMAs are use-
ful for the assessment of automated unsupervised image
analysis systems because of the careful selection of the
areas of interest, the identical staining conditions for all
cores on a single slide, and the small size of the tissue
cores representable by a single image [37,38,47]. Prob-
lems inherent in TMA studies include taking cores from
the non-cancerous areas, and a loss of cores during the
staining procedure. We analyzed the results of visual (two
pathologists) and automated (two operators on the Ariol
image analysis system) scoring of HER2 immunostaining.
Since only cores with more than 50 tumor cells detected
were considered scorable on the Ariol system, the number
of cases scorable by all four observers was 1,212. FISH was
successfully performed in 1,413 cases (34.9%) with an
amplification rate of 17.8%, which is within the reported
range of 10–35% [2-5].
When using the four-tier criteria for HER2 IHC (0 and 1+
negative, 3+ positive, and 2+ equivocal), the inter-
observer agreement is usually excellent for negative (0,
1+) and positive (3+) cases [11,16-19]. To estimate the
inter-observer variability in our study, we analyzed the
results of two visual and two automated scores. When
comparing binarized IHC scores, the inter-observer agree-
ment was excellent between the two pathologists (kappa
= 1.000, 95% CI: 1-1), between the two machines (kappa
= 1.000, 95% CI: 1-1), between both visual and both
machine scores (kappa = 0.898, 95% CI: 0.775–0.979).
This suggests that the Ariol automated system can be used
successfully for scoring clearly positive or negative cases,
whereas equivocal cases will always need follow-up
through pathologist review and/or FISH.
Since the evaluation of staining intensity and percentage
of cells with complete membrane positivity is subjective,
the inter-observer variability tends to be higher for scoring
2+ cases [11,17,20,21] and discriminating 1+ and 2+ [48]
or 2+ and 3+ cases [12]. The percentage of disagreement
in intraobserver reproducibility ranges from 0.9% to
3.7%. It is recommended that two expert pathologists
evaluate all slides with a double-blind method and dis-
cuss discordant cases [49]. In our study, the inter-observer
agreement was excellent for categorized variables (0, 1+
versus 2+ versus 3+) between the two pathologists (kappa
= 0.929, 95% CI: 0.909–0.946). The first machine scores
also showed excellent agreement with both pathologists
(kappa = 0.835, 95% CI: 0.806–0.862; kappa = 0.837,
95% CI: 0.81–0.862). The worst concordance for catego-
rized variables was observed between the second machine
Table 3: Kappa statistics for comparison of inter-observer concordance for binarized HER2 IHC variables (n = 849)
Visual 1 Visual 2 Machine 1
Visual 1 ---
Visual 2 1.000 (1 - 1) - -
Machine 1 0.898 (0.775 – 0.979) 0.898 (0.775 – 0.979) -
Machine 2 0.898 (0.775 – 0.979) 0.898 (0.775 – 0.979) 1.000 (1 - 1)
Table 4: Permutation test to determine the inter-observer 
variability for categorized IHC variables (n = 352)
Visual 1 Visual 2 Machine 1
Visual 1 ---
Visual 2 0.426 - -
Machine 1 1 × 10-4 0.001 -
Machine 2 1 × 10-4 1 × 10-4 1 × 10-4
Table 5: Concordance of IHC and FISH results by Kappa 
statistics
FISH vs categorized
IHC (n = 616)
FISH vs binarized
IHC (n = 382)
Visual 1 0.814 (0.768 – 0.856) 0.328 (0.0955 – 0.537)
Visual 2 0.763 (0.712 – 0.81) 0.328 (0.0914 – 0.538)
Machine 1 0.665 (0.609 – 0.718) 0.343 (0.101 – 0.558)
Machine 2 0.535 (0.485 – 0.584) 0.343 (0.0935 – 0.555)BMC Cancer 2009, 9:165 http://www.biomedcentral.com/1471-2407/9/165
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operated by a less experienced operator and either pathol-
ogist 1 (kappa = 0.698, 95% CI: 0.6723–0.723) or pathol-
ogist 2 (kappa = 0.709, 95% CI: 0.684–0.732) or the first
machine scores (kappa = 0.806, 95% CI: 0.785–0.826).
Although these kappa values are still considered to be in
good agreement, it is likely that lack of experience in oper-
ating the Ariol system using particular scripts can influ-
ence the results of automated scoring for categorized
variables. However, the results of the IHC analysis for cat-
egorized scores by either pathologists or machines dem-
onstrated similar accuracy in assessment of prognostic
significance of HER2 expression in Kaplan-Meier analysis.
Discrepancies between HER2 IHC and FISH results are
not uncommon and may be caused by errors in manual
IHC interpretation, IHC reagent limitations [50,51], dif-
ferent anti-HER2 primary antibodies [48,52-57], a lack of
interlaboratory standardization of IHC and reproducibil-
ity in interpretation of the results [58,59]. When compar-
ing categorized IHC scores and FISH results, only
pathologist 1 showed excellent agreement with FISH
results (kappa = 0.814, 95% CI: 0.768–0.856). There was
good agreement between FISH and pathologist 2 scores
(kappa = 0.763, 95% CI: 0.712–0.81), and machine 1
scores (kappa = 0.665, 95% CI: 0.609–0.718), while the
less experienced operator showed moderate agreement
with FISH results (kappa = 0.535, 95% CI: 0.485–0.584).
In addition to the amount of experience working with par-
ticular Ariol scripts, variations in the image analysis
results may depend on the scanner settings, such as cali-
bration, positioning and white balance because the image
analysis settings were transferred from the first Ariol sys-
tem to the other, without training the program. It should
also be noted that HER2 gene amplification is not always
accompanied by protein overexpression and vice versa.
The poor prognosis associated with HER2 amplification
may be attributed to global genomic instability, as cells
with high frequencies of chromosomal alterations are
associated with increased cellular proliferation and
aggressive behavior. This suggests that HER2 amplifica-
tion may serve as a surrogate marker for underlying
genomic instability [60]. The discrepancy between FISH
and IHC results can also be explained by technical and
interpretational limitations such as failure to hybridize,
scoring algorithm on the Metafer system, small size of the
TMA core making this small region not representative for
the tumor. For categorized variables, comparison of log-
rank tests with 10,000 permutations detected no signifi-
Table 6: Comparison of automated IHC scores with visual scores and FISH results
IHC/FISH Machine 1 Machine 2 Visual 1 Visual 2 FISH
Negative (IHC 0,1+/FISH <1.8) 434 445 415 431 394
Equivocal (IHC 2+/FISH 1.8–2.2) 1 0 5 1 6 3 5 24 83 7
Positive (IHC 3+/FISH >2.2) 77 8 149 137 185
Table 7: Clinical-pathological characteristics of 1212 patients
Variables No. %
Menstrual status Premenopausal 368 30.4
Postmenopausal 811 66.9
Unknown 33 2.7
LN status Negative 645 53.2
Positive 563 46.5
Unknown 40 . 3
Histological diagnosis Ductal 1149 94.8
Lobular 48 4
Other 15 1.2
Systemic therapy No adjuvant systemic therapy 484 39.9
Tamoxifen, no chemotherapy 398 32.8
Chemotherapy, no Tamoxifen 228 18.8
Chemotherapy and Tamoxifen 100 8.3
Ovarian ablation or hormono-therapy other than Tamoxifen, no chemotherapy 1 0.1
Ovarian ablation or hormono-therapy other than Tamoxifen, and chemotherapy 1 0.1BMC Cancer 2009, 9:165 http://www.biomedcentral.com/1471-2407/9/165
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cant differences among four observers. Two pathologists
successfully distinguished negative, positive and equivo-
cal cases, but automated scoring led to 2–3 times as many
2+ cases as visual scoring. This suggests that fully auto-
mated scoring, regardless of use experience, does not pro-
vide better distinction of 2+ cases in our study. This is
inconsistent with previously reported results that machine
scoring of HER2 is reproducible for 2+ cases [61]. How-
ever, the latter study only analyzed 65 cases using an
Extended Slide Wizard (Tripath Imaging, Inc., Burlington,
North Carolina, USA) workstation running prototype
software. In theory, computer-assisted image analysis
should provide more accurate results for IHC quantita-
tion, in comparison with semiquantitative scoring by a
pathologist, as image analysis systems can measure the
intensity of staining much more precisely than a human
eye [62]. In practice, however, the accuracy of automated
quantitative analysis depends on a variety of factors other
than technical issues. Fully automated systems cannot dis-
tinguish between malignant and benign lesions with a
precision comparable to the expertise level of a patholo-
gist [63,64], and require pathologist input to identify the
area to be analyzed. Since the machine interprets most vis-
ual 3+ scores as 2+, it is likely that automated HER2 scor-
ing on the Ariol system would result in more FISH
assessments in clinical practice. The automated system
Kaplan-Meier survival analysis performed on the data categorized as negative (0, 1+), equivocal (2+) and positive (3+) (n =  1210) Figure 2
Kaplan-Meier survival analysis performed on the data categorized as negative (0, 1+), equivocal (2+) and posi-
tive (3+) (n = 1210). a) Visual scoring #1. b) Visual scoring #2. c) Automated system #1. d) Automated system #2.
(a) Visual 1  (b) Visual 2
(c) Machine 1  (d) Machine 2BMC Cancer 2009, 9:165 http://www.biomedcentral.com/1471-2407/9/165
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Kaplan-Meier survival analysis performed on the binarized data (negative {0, 1+} and positive {3+}) (n = 848) Figure 3
Kaplan-Meier survival analysis performed on the binarized data (negative {0, 1+} and positive {3+}) (n = 848). a) 
Visual scoring #1. b) Visual scoring #2. c) Automated system #1. d) Automated system #2.
(a) Visual 1  (b) Visual 2
(c) Machine 1  (d) Machine 2
Table 8: Permutation test to compare the differences between categorized IHC and FISH results using survival outcome as the gold 
standard (n = 615)
FISH Visual 1 Visual 2 Machine 1
FISH - ---
Visual 1 0 . 3 5 2 ---
Visual 2 0.562 0.695 - -
Machine 1 0.441 0.982 0.811 -
Machine 2 0.214 0.472 0.332 0.484BMC Cancer 2009, 9:165 http://www.biomedcentral.com/1471-2407/9/165
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also leads to more 1+ cases in comparison to visual scor-
ing, which may give rise to more FISH-amplified cases to
be scored as 1+ (negative). However, this would not
change patient management for 0 and 1+ cases as these
are both interpreted as negative.
Conclusion
The present study shows that fully automated image anal-
ysis with a system operated by an experienced operator,
but without continuous human supervision, can provide
results consistent with the scoring of HER2 immunostain-
ing by pathologists. The inter-observer agreement was
excellent between the two pathologists and between the
experienced operator and the pathologists for both bina-
rized and categorized HER2 scores, as well as between the
two machines for binarized scores. There was a good
agreement between the two machines, and between the
less experienced operator and the pathologists for catego-
rized HER2 scores. We have previously reported that auto-
mated quantitation of ER immunostaining on the same
TMA series can produce results that do not differ from
pathologist scoring and dextran-coated charcoal bio-
chemical assay [28]. Unlike ER quantitation, automated
scoring of HER2 staining on the Ariol system did not pro-
vide excellent agreement between machine scores or the
gold standard FISH. Although Kaplan-Meier analysis
showed similar accuracy of visual and machine scores in
assessment of prognostic significance of HER2 status for
categorized IHC variables, the automated quantitation
could not distinguish 2+ scores better than the patholo-
gists. It resulted in more 2+ cases which would lead to
more FISH assessments in clinical practice. Further devel-
opment of image analysis systems will likely improve the
accuracy of detection and categorization of membranous
staining in histological sections, making this technique
more sensitive, specific and thus suitable for use in quality
assurance programs.
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